Clinical predictors of long-term outcome in obsessive-compulsive disorder

Depression and Anxiety

Volumn 30, Issue 8, 2013, Pages 763-772

  Jakubovski, Ewgeni ^a   Diniz, Juliana B ^b   Valerio, Carolina ^b   Fossaluza, Victor ^b   Belotto Silva, Cristina ^b   Gorenstein, Clarice ^b   Miguel, Eurípedes ^b   Shavitt, Roseli G ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

cognitive therapy; drug therapy; fluoxetine; follow up studies; obsessive compulsive disorder

Indexed keywords

FLUOXETINE;

ADULT; ANXIETY DISORDER; ARTICLE; BECK DEPRESSION INVENTORY; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DSM-IV; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; TIC; TREATMENT DURATION; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

COGNITIVE THERAPY; DRUG THERAPY; FLUOXETINE; FOLLOW-UP STUDIES; OBSESSIVE-COMPULSIVE DISORDER;

ADULT; AGE FACTORS; AGE OF ONSET; COGNITIVE THERAPY; DEPRESSIVE DISORDER; FEMALE; FLUOXETINE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; PROGNOSIS; PSYCHOTHERAPY, GROUP; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84881478070     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22013     Document Type: Article

References (57)

1. Lensi P, Cassano GB, Correddu G, et al. Obsessive-compulsive disorder. Familial-developmental history, symptomatology, comorbidity and course with special reference to gender-related differences. Br J Psychiatry 1996; 169: 101-107.
2. Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive compulsive disorder. J Clin Psychiatry 1994; 55 (Suppl): 5-10; discussion 11-4.
3. Pollitt J,. Natural history of obsessional states; a study of 150 cases. Br Med J 1957; 1: 194-198.
4. Warren W,. Some relationships between the psychiatry of children and of adults. J Ment Sci 1960; 106: 815-826.
5. Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder [see comments]. Arch Gen Psychiatry 1999; 56: 121-127.
6. Eisen JL, Goodman WK, Keller MB, et al. Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. J Clin Psychiatry 1999; 60: 346-351; quiz 352.
7. Eisen JL, Pinto A, Mancebo MC, et al. A 2-year prospective follow-up study of the course of obsessive-compulsive disorder. J Clin Psychiatry 2010; 71: 1033-1039.
8. Marks IM, Hodgson R, Rachman S,. Treatment of chronic obsessive-compulsive neurosis by in-vivo exposure. A two-year follow-up and issues in treatment. Br J Psychiatry 1975; 127: 349-364.
9. O'Sullivan G, Noshirvani H, Marks I, et al. Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder. J Clin Psychiatry 1991; 52: 150-155.
10. de Haan E, van Oppen P, van Balkom AJ, et al. Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy. Acta Psychiatr Scand 1997; 96: 354-361.
11. Alonso P, Menchon JM, Pifarre J, et al. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry 2001; 62: 535-540.
12. Thomsen PH,. Obsessive-compulsive disorder in children and adolescents. A 6-22 year follow-up study of social outcome. Eur Child Adolesc Psychiatry 1995; 4: 112-122.
13. Flament MF, Koby E, Rapoport JL, et al. Childhood obsessive-compulsive disorder: a prospective follow-up study. J Child Psychol Psychiatry 1990; 31: 363-380.
14. Orloff LM, Battle MA, Baer L, et al. Long-term follow-up of 85 patients with obsessive-compulsive disorder. Am J Psychiatry 1994; 151: 441-442.
15. Leonard HL, Swedo SE, Lenane MC, et al. A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry 1993; 50: 429-439.
16. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51: 302-308.
17. Allsopp M Verduyn C. A follow-up of adolescents with obsessive-compulsive disorder. Br J Psychiatry 1989; 154: 829-834.
18. Alarcon RD, Libb JW, Spitler D,. A predictive study of obsessive-compulsive disorder response to clomipramine. J Clin Psychopharmacol 1993; 13: 210-213.
19. Ackerman DL, Greenland S, Bystritsky A,. Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1998; 18: 185-192.
20. Price LH, Goodman WK, Charney DS, et al. Treatment of severe obsessive-compulsive disorder with fluvoxamine. Am J Psychiatry 1987; 144: 1059-1061.
21. Braga DT, Cordioli AV, Niederauer K, Manfro GG,. Cognitive-behavioral group therapy for obsessive-compulsive disorder: a 1-year follow-up. Acta Psychiatr Scand 2005; 112: 180-186.
22. Miguel EC, Leckman JF, Rauch S, et al. Obsessive-compulsive disorder phenotypes: implications for genetic studies. Mol Psychiatry 2005; 10: 258-275.
23. Shavitt RG, Belotto C, Curi M, et al. Clinical features associated with treatment response in obsessive-compulsive disorder. Compr Psychiatry 2006; 47: 276-281.
24. Ferrao YA, Shavitt RG, Bedin NR, et al. Clinical features associated to refractory obsessive-compulsive disorder. J Affect Disord 2006; 94: 199-209.
25. Belotto-Silva C, Diniz JB, Malavazzi DM, et al. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial. J Anxiety Disord 2012; 26: 25-31.
26. Diniz JB, Shavitt RG, Fossaluza V, et al. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol 2011; 31: 763-768.
27. Diniz JB, Shavitt RG, Pereira CA, et al. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J Psychopharmacol 2010; 24: 297-307.
28. First MB, Spitzer RL, Gibbon M, Williams JB,. Structured Clinical Interview for DSM-IV Axis I Disorders: Clinical Version (SCID-CV). Washington, DC: American Psychiatric Press, 1997.
29. Rosario-Campos MC, Miguel EC, Quatrano S, et al. The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions. Mol Psychiatry 2006; 11: 495-504.
30. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-1011.
31. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
32. Beck AT, Epstein N, Brown G, Steer RA,. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893-897.
33. Miguel EC, Ferrao YA, Rosario MC, et al. The Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders: recruitment, assessment instruments, methods for the development of multicenter collaborative studies and preliminary results. Rev Bras Psiquiatr 2008; 30: 185-196.
34. Fossaluza V, Diniz JB, Pereira Bde B, et al. Sequential allocation to balance prognostic factors in a psychiatric clinical trial. Clinics (Sao Paulo) 2009; 64: 511-518.
35. Volpato Cordioli A, Heldt E, Braga Bochi D, et al. Cognitive-behavioral group therapy in obsessive-compulsive disorder: a randomized clinical trial. Psychother Psychosom 2003; 72: 211-216.
36. SPPS Inc. PASW Statistics 18.0. Chicago IL: SPSS Inc., 2009.
37. Singer JM, Poleto FZ, Rosa P,. Parametric and nonparametric analyses of repeated ordinal categorical data. Biom J 2004; 46: 460-473.
38. Belotto-Silva C, Diniz JB, Shavitt RG,. Psychological treatment of obsessive-compulsive disorder in patients with psychiatric comorbidity. Can J Psychiatry 2011; 56: 127.
39. Zitterl W, Demal U, Aigner M, et al. Naturalistic course of obsessive compulsive disorder and comorbid depression. Longitudinal results of a prospective follow-up study of 74 actively treated patients. Psychopathology 2000; 33: 75-80.
40. Tolin DF, Maltby N, Diefenbach GJ, et al. Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial. J Clin Psychiatry 2004; 65: 922-931.
41. Steketee G, Eisen J, Dyck I, et al. Predictors of course in obsessive-compulsive disorder. Psychiatry Res 1999; 89: 229-238.
42. Abramowitz J, Franklin M, Street G, et al. Effects of comorbid depression on response to treatment for obsessive-complusive disorder. Behav Ther 2000; 31: 517-528.
43. Valerio C, Diniz JB, Fossaluza V, et al. Does anti-obsessional pharmacotherapy treat so-called comorbid depressive and anxiety states? J Affect Disord 2012; 139: 187-92.
44. Catapano F, Perris F, Masella M, et al. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study. J Psychiatr Res 2006; 40: 502-510.
45. Ravizza L, Barzega G, Bellino S, et al. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry 1995; 56: 368-373.
46. Pauls DL, Alsobrook JP, 2nd, Goodman W, et al. A family study of obsessive-compulsive disorder. Am J Psychiatry 1995; 152: 76-84.
47. de Mathis MA, do Rosario MC, Diniz JB, et al. Obsessive-compulsive disorder: influence of age at onset on comorbidity patterns. Eur Psychiatry 2008; 23: 187-194.
48. de Mathis M, Diniz J, Shavitt R, et al. Early onset obsessive-compulsive disorder with and without tics. CNS Spectr 2009; 14: 362-370.
49. Diniz JB, Rosario-Campos MC, Shavitt RG, et al. Impact of age at onset and duration of illness on the expression of comorbidities in obsessive-compulsive disorder. J Clin Psychiatry 2004; 65: 22-27.
50. Fontenelle L, do Rosário-Campos M, Mendlowicz M, et al. Treatment-response by age at onset in obsessive-compulsive disorder. J Affect Disord 2004; 83: 283-284.
51. Foa EB, Grayson JB, Steketee GS, et al. Success and failure in the behavioral treatment of obsessive-compulsives. J Consult Clin Psychol 1983; 51: 287-297.
52. Foa EB, Kozak MJ, Steketee GS, McCarthy PR,. Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behaviour therapy. Br J Clin Psychol 1992; 31 (Pt 3): 279-292.
53. Sousa MB, Isolan LR, Oliveira RR, et al. A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 2006; 67: 1133-1139.
54. Anderson RA Rees CS. Group versus individual cognitive-behavioural treatment for obsessive-compulsive disorder: a controlled trial. Behav Res Ther 2007; 45: 123-137.
55. McLean PD, Whittal ML, Thordarson DS, et al. Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder. J Consult Clin Psychol 2001; 69: 205-214.
56. Diniz JB, Malavazzi DM, Fossaluza V, et al. Risk factors for early treatment discontinuation in patients with obsessive-compulsive disorder. Clinics (Sao Paulo) 2011; 66: 387-393.
57. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005; 162: 151-161.